Enveric Biosciences Collaborates with Aries Science & Technology to Develop its Dermatitis Topical Product
Shots:
- Enveric Biosciences and Aries Science & Technology have entered into a licensing agreement to develop the former’s radiation dermatitis topical product
- As per the agreement, Aries will pay a total of ~$61M milestones plus additional 2.5% to 10% sales-based tiered royalties, on meeting all the conditions. Agreement will be executed through Akos Biosciences (subsidiary of Enveric)
- This product aims to relieve cancer patients from the painful side effects of radiation therapy. It is protected by an allowed US patent & a pending PCT application
Ref: Enveric Biosciences | Image: Enveric Biosciences
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
